RMCM
VRTX icon

Reynders McVeigh Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Reynders McVeigh Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1M Sell
54,499
-165
-0.3% -$73.1K 1.2% 27
2026
Q1 		$24.4M Buy
54,664
+759
+1% +$354K 1.23% 29
2025
Q4 		$24.4M Sell
53,905
-1,445
-3% -$623K 1.15% 28
2025
Q3 		$21.7M Buy
55,350
+1,040
+2% +$435K 1.02% 34
2025
Q2 		$24.2M Buy
54,310
+974
+2% +$449K 1.21% 32
2025
Q1 		$25.9M Buy
53,336
+1,082
+2% +$504K 1.44% 30
2024
Q4 		$21M Buy
52,254
+3,524
+7% +$1.63M 1.11% 34
2024
Q3 		$22.7M Buy
48,730
+6,269
+15% +$3.01M 1.2% 32
2024
Q2 		$19.9M Buy
42,461
+11,860
+39% +$5.15M 1.13% 31
2024
Q1 		$12.8M Buy
30,601
+14,460
+90% +$6.11M 0.74% 41
2023
Q4 		$6.57M Buy
16,141
+2,070
+15% +$765K 0.42% 47
2023
Q3 		$4.89M Buy
14,071
+4,689
+50% +$1.64M 0.34% 50
2023
Q2 		$3.3M Buy
9,382
+5,410
+136% +$1.82M 0.22% 57
2023
Q1 		$1.25M Buy
3,972
+2,547
+179% +$764K 0.09% 83
2022
Q4 		$412K Buy
+1,425
New +$434K 0.03% 152

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Reynders McVeigh Capital Management's VRTX Position: Q2 2026 in Review

Reynders McVeigh Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.3% in Q2 2026, selling an estimated $73.1K and leaving 54,499 shares worth $27.1M. The position accounts for 1.2% of the portfolio, ranked #27.

Reynders McVeigh Capital Management first reported a position in VRTX in Q4 2022 and has held it in 15 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Reynders McVeigh Capital Management held 54,499 shares of Vertex Pharmaceuticals worth $27.1M as of Q2 2026.
  • Reynders McVeigh Capital Management sold 165 Vertex Pharmaceuticals shares in Q2 2026, an estimated $73.1K.
  • Vertex Pharmaceuticals made up 1.2% of Reynders McVeigh Capital Management's portfolio in Q2 2026, its #27 holding.
  • Reynders McVeigh Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Reynders McVeigh Capital Management's 13F filing for Q2 2026, filed 15 Sep 2026.